Episode 72: Nefecon for IgAN, The NefIgArd part B trial

The Filtrate:

Joel Topf

Josh Waitzman

With Special Guest:

Brad Rovin (@BradRovin) Chief of nephrology at The Ohio State University Wexner Medical Center, one of the authors of the Nefigard trial.

Koyal Jain (@koyaljainMD) Program director of the GN Fellowship at University of North Carolina

Roger Rodby (@NephRodby) Associate program director of the Rush University Nephrology Fellowship

Editor

Sophia Ambruso

Show Notes

The manuscript (The Lancet | PubMed | NephJC)

The Results of Part A (Kidney Int | PubMed)

Edmund (Ed) Louis memorium by Steve Korbet in KI

Steve Korbet Do not miss this tweet

TESTING Freely Filtered #48 with Sean Barbour

Iptapocan at the World Congress of Nephrology: WCN24-1506 Efficacy And Safety Of Iptacopan In Patients With IgA Nephropathy: Interim Results From The Phase 3 APPLAUSE-IgAN Study

FDA and mandatory post-marketing studies. What happens when the study is negative (or not completed) (UNDARK)

Who should treat lupus nephritis: rheumatologists or nephrologists? (Nature Reviews Nephrology)

Protein and albumin-to-creatinine ratios in random urines accurately predict 24 h protein and albumin loss in patients with kidney disease (PubMed)

MEST Scores in NephJC

Risk scores in IgAN in NephJC

Repeat renal biopsy improves the Oxford classification-based prediction of immunoglobulin A nephropathy outcome (NDT)

Tarpeyo pills 4 mg. Four pills once a day. (WellRx has a picture of the pills)

IgA nephropathy in African Americans: uncommon but possible (PubMed Central)

Aberrantly Glycosylated IgA1 in IgA Nephropathy: What We Know and What We Don’t Know (PubMed Central)

Effectiveness of Mycophenolate Mofetil Among Patients With Progressive IgA Nephropathy (JAMA Network Open)

Tubular Secretions

Joel: Constellation on Apple TV (Wikipedia). Not good. Dune audio books are excellent. (